Clarivate Q2 2023 Earnings Report
Key Takeaways
Clarivate reported a decrease in revenues by 2.6% to $668.8 million, driven by the divestiture of MarkMonitor. Organic revenues decreased slightly by 0.4%. Net loss attributable to ordinary shares was $141.7 million. Adjusted EBITDA increased by 3.8% to $284.9 million, with an Adjusted EBITDA Margin of 42.6%.
Revenues decreased by 2.6% to $668.8 million, and 3.5% at constant currency.
Organic revenues decreased 0.4%, with subscription revenues increasing 2.9% but offset by declines in re-occurring and transactional revenues.
Net loss attributable to ordinary shares was $141.7 million.
Adjusted EBITDA increased 3.8% to $284.9 million, with an Adjusted EBITDA Margin of 42.6%.
Clarivate
Clarivate
Forward Guidance
Clarivate revised its 2023 outlook due to lower than expected transactional sales of Life Sciences and Healthcare products and consulting services, and lower recurring sales of patent renewals. The company reaffirmed its Adjusted EBITDA Margin outlook, and still expects revenues, Adjusted EBITDA, Adjusted Diluted EPS and Free Cash Flow to be within the original ranges.
Positive Outlook
- Revenues between $2.60B to $2.67B
- Organic Revenue Growth between 0.00% to 2.00%
- Adjusted EBITDA between $1.09B to $1.14B
- Adjusted EBITDA Margin between 42.0% to 42.5%
- Free Cash Flow between $450M to $500M
Challenges Ahead
- Lower than expected transactional sales of Life Sciences and Healthcare products and consulting services
- Lower recurring sales of patent renewals
- Assumes no further acquisitions, divestitures, or unanticipated events
- Revenue outlook decreased from $2.63B to $2.73B to $2.60B to $2.67B
- Organic Revenue Growth decreased from 2.75% to 3.75% to 0.00% to 2.00%